ResMed RMD EBITDA
Discontinued — last reported Q3 '26
EBITDA at other companies
Other financials
Where this comes from
Calculated from ResMed’s reported figures.
The official record: ResMed’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about ResMed's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ResMed's EBITDA?
- ResMed (RMD) reported EBITDA of $558.79M in Q1 2026.
- How has ResMed's EBITDA changed year-over-year?
- ResMed's EBITDA increased by 18.9% year-over-year, from $469.94M to $558.79M.
- What is the long-term trend for ResMed's EBITDA?
- Over 4 years (2021 to 2025), ResMed's EBITDA has grown at a 15.4% compound annual growth rate (CAGR), from $1.06B to $1.88B.
- What does EBITDA mean?
- Operating cash profit before interest, taxes, and non-cash charges.
- How do you interpret EBITDA?
- Higher is better and widely used to value capital-intensive businesses, but it ignores the real cost of capex — pair it with free cash flow. (Defined as EBIT + D&A so EBITDA = EBIT + D&A holds exactly.)
- How does EBITDA compare across companies?
- Standard cross-company operating-profit proxy for non-financials; not meaningful for banks and insurers.